Orion Biotech Opportunities shares and warrants may be traded separately starting today, the SPAC said. Those units not separated will continue to trade on the Nasdaq under ORIAU. Shares and warrants that are separated will trade under ORIA and ORIAW.
Orion raised $200 million in a May IPO. The SPAC is targeting companies in a growth-oriented sector, including technology and media.
The SPAC is led by CEO and Director James Huang, a founding managing partner of VC firm Panacea Venture. Huang is also a managing partner of Kleiner Perkins Caufield & Byers China. Read more.
